Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131885 | 0.90 | ATM (0.67) | LMNAPOLBATMDRD2DRD4 | |
| SCHEMBL6030972 | 0.89 | ATM (0.62) | LMNAATMADRA1DADRA1AADRA1B | |
| SCHEMBL11550567 | 0.88 | ATM (0.61) | LMNAATMADRA1DADRA1AADRA1B | |
| SCHEMBL18171326 | 0.88 | MAPK1 (0.70) | ATMADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL18177896 | 0.88 | ATM (0.64) | ATMADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL3436468 | 0.84 | ATM (0.57) | LMNAATMGAAADRA1DADRA1A | |
| SCHEMBL20157076 | 0.84 | DRD2 (0.62) | LMNAATMGAADRD2DRD4 | |
| SCHEMBL17696006 | 0.84 | ATM (0.60) | LMNAATMADRA1DADRA1AADRA1B | |
| SCHEMBL8168762 | 0.83 | LMNA (0.66) | LMNAPOLBATMGAADRD2 | |
| SCHEMBL18177900 | 0.83 | DRD2 (0.61) | LMNAPOLBATMDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | claimed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | claimed |
| US-20040083447-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-04-29 | — | — | US | claimed |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-06-26 | — | — | US | claimed |
| US-6426347-B2 | FOR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION | 2002-07-30 | — | — | US | claimed |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | THURKAUF ANDREW (US) | 2002-01-17 | — | — | US | claimed |
| JP-2001521492-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | claimed |
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040083447-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-04-29 | — | — | US | disclosed |
| US-6656943-B2 | In the treatment or prevention of psychotic disorders such as schizophrenia psychotic depression, mania and other central nervous system diseases | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-6172229-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5859246-A | TREATING NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | LMNA 3652/4885POLB 2635/4885ATM 4410/4885 |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | LMNA 3853/4885POLB 2593/4885ATM 4707/4885 |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | LMNA 3853/4885POLB 2593/4885ATM 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.